口咽鳞癌选择性淋巴结照射个体化减量研究方案(DeEscO)
本研究为多中心前瞻性单臂试验方案,基于598例口咽鳞癌患者淋巴结受累数据建立淋巴转移模型,制定依据T分期、中线扩展及临床淋巴结受累组合的个体化选择性CTV。主要终点为2年野外淋巴结复发率,计划在瑞士6个中心入组120例患者。
要点
- 基于T分期、中线扩展和临床淋巴结受累制定个体化选择性CTV减量方案。
- 主要终点为2年野外淋巴结复发率,计划入组120例,瑞士6中心参与。
- 目标是通过减量放疗降低治疗相关毒性并改善生活质量。
核心结论
- 个体化减量选择性淋巴结照射旨在降低口咽鳞癌患者放疗毒性并改善生活质量,其疗效与安全性待前瞻性试验验证。
研究设计与样本
- 多中心前瞻性单臂试验,计划在瑞士6个中心入组120例口咽鳞癌患者。
- 基于598例多机构口咽鳞癌患者详细淋巴结受累数据建立淋巴肿瘤进展模型,估计临床阴性淋巴结水平的隐匿转移概率。
- 试验注册号NCT06563362,注册日期2024年8月20日;伦理批准日期2025年1月21日,BASEC编号2024-01936,方案版本2.1(2025年5月12日)。
主要发现
- 基于模型和临床判断创建表格,定义不同T分期、中线扩展和临床淋巴结水平受累组合下的个体化选择性CTV。
- 数据集可在https://lyprox.org/可视化。
关键数值与推荐
- 主要终点为2年野外淋巴结复发率。
- 个体化选择性CTV依据T分期、中线扩展和临床淋巴结水平受累的组合确定。
临床怎么用
- 根据T分期、中线扩展和临床淋巴结受累组合查表确定个体化选择性CTV,以实现选择性淋巴结照射减量。
局限性
- 原文未报告试验结果,疗效与安全性尚待验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Definitive (chemo)radiotherapy of oropharyngeal squamous cell carcinoma (SCC) consists of treatment of the macroscopic tumor and prophylactic irradiation of the lymphatic drainage system: the elective clinical target volume (CTV). In this study, we reduce the elective CTV based on the personalized factors T-stage, clinical lymphatic involvement, and lateralization of the primary tumor. METHODS: The primary objective is to evaluate efficacy and safety of an individualized de-escalation of elective node irradiation volumes. We collected a multi-institutional dataset of 598 oropharyngeal SCC patients in whom detailed lymph node involvement was reported. Based on the data, we developed a model of lymphatic tumor progression to estimate the probability of occult metastases in the clinically negative lymph node levels (LNLs). The dataset can be visualized on https://lyprox.org/. Based on this model and clinical judgement, we created tables that define the personalized elective CTV for different combinations of T-stage, midline extension and clinical LNL involvement. The primary endpoint of this multicentric, prospective, single-arm trial is the rate of out-of-field nodal recurrences after 2 years. The study will be conducted in 6 centers across Switzerland and 120 patients will be enrolled. DISCUSSION: This study sets out to personalize the elective CTV in oropharyngeal SCC patients, with the goal to de-escalate radiotherapy for patients and herewith improve therapy-associated toxicity and quality of life. The results of this study may be used to personalize treatment in oropharyngeal SCC patients. TRIAL REGISTRATION: The trial was registered on ClinicalTrials.gov NCT06563362, on 20/08/2024. Ethical approval was obtained on 21/01/2025, BASEC-Nr 2024-01936. Protocol Version 2.1, 12/05/2025.
引用
- Looman EL, Pérez Haas Y, Ludwig R, et al. Personalized volume de-escalated elective nodal irradiation in oropharyngeal squamous cell carcinoma (DeEscO): a study protocol. Clin Transl Radiat Oncol. 2026. PMID: 42200110. doi:10.1016/j.ctro.2026.101182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。